NSAIDs increase survival in the Sandhoff disease mouse: Synergy with N-butyldeoxynojirimycin

Annals of Neurology

Volumn 56, Issue 5, 2004, Pages 642-649

  Jeyakumar, Mylvaganam ^a   Smith, David A ^a   Williams, Ian M ^a   Borja, Mario Cortina ^b   Neville, David C A ^a   Butters, Terry D ^a   Dwek, Raymond A ^a   Platt, Frances M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; GLUCOSYLCERAMIDASE; GLYCOSPHINGOLIPID; IBUPROFEN; INDOMETACIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MIGLUSTAT; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG POTENTIATION; ENZYME DEFICIENCY; GM2 GANGLIOSIDOSIS; LIPID PEROXIDATION; LYSOSOME STORAGE DISEASE; MOTOR COORDINATION; MOTOR PERFORMANCE; MOUSE; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; SANDHOFF DISEASE; SURVIVAL;

1-DEOXYNOJIRIMYCIN; AGE FACTORS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-OBESITY AGENTS; BEHAVIOR, ANIMAL; BLOTTING, WESTERN; BRAIN; CYCLOOXYGENASE 2; DINOPROSTONE; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLUTATHIONE; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNOHISTOCHEMISTRY; ISOENZYMES; LIPID PEROXIDATION; MICE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PSYCHOMOTOR PERFORMANCE; SANDHOFF DISEASE; SPINAL CORD; SURVIVAL RATE; TIME FACTORS; VITAMIN A;

EID: 9144261868     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20242     Document Type: Article

References (25)

1. Scriver CR, Beaudet AL, Sly WS, Valle D. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw Hill, 2001:3371-3896.
2. Platt FM, Walkley SU. Lysosomal disorders of the brain. 1st ed. Oxford: Oxford University Press, 2004:1-447.
3. Platt FM, Neises GR, Dwek RA, Butters TD. N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J Biol Chem 1994;269:8362-8365.
4. Dwek RA, Butters TD, Platt FM, Zitzmann N. Targeting glycosylation as a therapeutic approach. Nat Rev Drug Discov 2002;1:65-75.
5. Lachmann RH. Miglustat. Oxford GlycoSciences/Actelion. Curr Opin Investig Drugs 2003;4:472-479.
6. Cox T, Lachmann R, Hollak C, et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000;355:1481-1485.
7. Wada R, Tifft CJ, Proia RL. Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation. Proc Natl Acad Sci U S A 2000;97:10954-10959.
8. Jeyakumar M, Thomas R, Elliot-Smith E, et al. Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain 2003;126:974-987.
9. Sango K, Yamanaka S, Hoffmann A, et al. Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism. Nat Genet 1995;11:170-176.
10. Platt FM, Neises GR, Reinkensmeier G, et al. Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science 1997;276:428-431.
11. Jeyakumar M, Butters TD, Cortina-Borja M, et al. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc Natl Acad Sci U S A 1999;96:6388-6393.
12. Esterbauer H, Cheeseman KH. Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Methods Enzymol 1990;186:407-421.
13. Myerowitz R, Lawson D, Mizukami H, et al. Molecular pathophysiology in Tay-Sachs and Sandhoff diseases as revealed by gene expression profiling. Hum Mol Genet 2002;11:1343-1350.
14. Yamaguchi A, Katsuyama K, Nagahama K, et al. Possible role of autoantibodies in the pathophysiology of GM2 gangliosidoses. J Clin Invest 2004;113:200-208.
15. Gao HM, Liu B, Zhang W, Hong JS. Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol Sci 2003;24:395-401.
16. Minghetti L, Levi G. Microglia as effector cells in brain damage and repair: focus on prostanoids and nitric oxide. Prog Neurobiol 1998;54:99-125.
17. Perry VH, Newman TA, Cunningham C. The impact of systemic infection on the progression of neurodegenerative disease. Nat Rev Neurosci 2003;4:103-112.
18. Netland EE, Newton JL, Majocha RE, Tate BA. Indomethacin reverses the microglial response to amyloid beta-protein. Neurobiol Aging 998;19:201-204.
19. Kurkowska-Jastrzebska I, Babiuch M, Joniec I, et al. Indomethacin protects against neurodegeneration caused by MPTP intoxication in mice. Im Immunopharmacol 2002;2:1213-1218.
20. Lim GP, Yang F, Chu T, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 2000;20:5709-5714.
21. Lim GP, Yang F, Chu T, et al. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol Aging 2001;22:983-991.
22. Aubin N, Curet O, Deffois A, Carter C. Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J Neurochem 1998;71:1635-1642.
23. Barneoud P, Curet O. Beneficial effects of lysine acetylsalicylate, a soluble salt of aspirin, on motor performance in a transgenic model of amyotrophic lateral sclerosis. Exp Neurol 1999;155:243-251.
24. Klivenyi P, Kiaei M, Gardian G, et al. Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem 2004;88:576-582.
25. Wu YP, Proia RL. Deletion of macrophage-inflammatory protein 1 alpha retards neurodegeneration in Sandhoff disease mice. Proc Natl Acad Sci U S A 2004;101:8425-8430.